I just emailed a link to my member’s report Curing Malaria, Killing Cancer: How Ibex Biosciences Could Save Millions and Transform Medicine to . The report is about a tiny American biotech company. When I looked into this company, my interest was piqued by the immense promise I saw from its discoveries and the potential for the many cures that those discoveries, and their application, can bring.

And as a successful technology investor, I believe that this is an excellent time to consider investing in the company. I’ve described how to invest in the company in the report.

Here’s a link to the report.

I initially sent the report to my Private Reserve members. Members of my Private Reserve get access to the kind of private placements, Pre-IPO, Reg D or Reg A opportunities that few others ever get to see..

Another small company that I alerted my members to (it’s barely two years old!) was awarded millions of dollars in government defense contracts and boasts a client list that includes Blue Origin.

It’s still so secret that only a few on Wall Street even know it exists.

See for yourself why that company might not be small for very long!

I’ll be in touch over the next days with some more thoughts on the opportunities presented by these two findings, and with more about the benefits of Private Reserve.

Good Investing,

George Gilder, Richard Vigilante, Steve Waite, John Schroeter, and Robert Castellano
Editors, Gilder’s Guideposts, Technology Report, Technology Report Pro, Moonshots, and Private Reserve

Editor’s Note: Remember, if you visit my website now you can sign up for Private Reserve like anyone can. Except that it will cost you the full, published “public” price of $4,995.

To find out more about the small company that few on Wall Street have heard of, and get Private Reserve for a full year at a fraction of the public price, follow this link.